
    
      Part 11 is a 24-week, randomized, double-blind, parallel-group, placebo-controlled assessment
      of the efficacy and safety of single daily subcutaneous (SC) doses of 40 mg elamipretide (vs
      placebo) administered with the elamipretide delivery system as a treatment for subjects with
      primary mitochondrial myopathy (PMM). Part 2 was to assess the long-term safety and
      tolerability of single daily SC doses of 40 mg elamipretide administered with the
      elamipretide delivery system for up to 144 weeks.
    
  